New Trends and Challenges in Pharmacogenomics Research
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: 15 August 2025 | Viewed by 281
Special Issue Editor
Interests: genomics; pharmacogenomics; drug metabolism; genetic epidemiology; cardiometabolic disorders; gout; uric acid
Special Issue Information
Dear Colleagues,
The field of pharmacogenomics is rapidly growing due to major advancements in sequencing technology. While pharmacogenomics has shown promise in reducing the burden of drug adverse events, the adoption of pharmacogenomics into routine practice has been lagging. Compounded by the limited sample size, the role of pharmacogenomics in early drug development programs remains limited to fully characterize the effect of genetic variability on drug response.
This Special Issue aims to highlight the trends, barriers, and opportunities to move pharmacogenomics from the bench to bed and back again. When shifting from a single gene variant to a polygenic risk assessment to predict the response, novel approaches to account for common and rare variants to assess the patient’s overall response are needed. These approaches will likely be able to optimize patient treatment outcomes as well as the selection of patients in clinical trials. We welcome the submission of both research and review articles to this Special Issue.
Prof. Dr. Youssef Roman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug development
- polygenic risk scores
- diversity and inclusion
- complex disease management
- implementation science
- genetic ancestry
- special populations
- rare variants
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
